BWIN必赢国际

    公司产品2024年批签发情况

    发布时间：

    2024-03-07

    作者：

    来源：

    摘要

    The company's product 2024 annual batch issuance situation is as follows:

    公司产品2024年批签发情况如下表：

    The company's product 2024 annual batch issuance situation is as follows:

    序号

    Serial No.

    产品名称

    Product Name

    批次

    Batch

    1

    无细胞百白破b型流感嗜血杆菌联合疫苗

    Diphtheria, Tetanus, Acellular Pertussis and Haemophilus influenzae type b combined vaccine

    27 批

    27 batch

    2

    23价肺炎球菌多糖疫苗

    23-valent pneumococcal polysaccharide vaccine

    11 批

    11 batch

    3

     13价肺炎球菌多糖结合疫苗（破伤风类毒素/白喉类毒素）

    13- valent pneumococcal polysaccharide conjugate vaccine(TT/DT)

    22 批

    22 batch

    4

    吸附无细胞百白破联合疫苗

    Diphtheria, Tetanus and Acellular Pertussis combined vaccine，Adsorbed

    4 批

    4batch

       5

    冻干b型流感嗜血杆菌结合疫苗

    Haemophilus Influenzae Type b Conjugate Vaccine, Freeze-dried

    11 批

    11 batch

    6

    冻干人用狂犬病疫苗（人二倍体细胞）

    Rabies Vaccine (Human Diploid Cell) for Human Use, Freeze-dried

    42 批

    42 batch

    7

    水痘减毒活疫苗

    Varicella Vaccine, Live

    3 批

    3 batch

    批签发公示：http://bio.nifdc.org.cn/pqf/search.do?formAction=pqfGs

    Batch release announcement:http://bio.nifdc.org.cn/pqf/search.do?formAction=pqfGs